Lilotomab

DB19076InvestigationalProtein Based Therapies

Lilotomab is under investigation in clinical trial NCT01796171 (A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-hodgkin Lymphoma).

Mechanism
Curator reviewed
Also known as
Immunoglobulin g1, anti-(human cd antigen cd37) (mus musculus monoclonal hh1 heavy chain), disulfide with mus musculus monoclonal hh1 light chain, dimer
Code names
HH1

Resolves to

Compound
UNII58I6YNR7BVCAS1453362-55-4
Targets
P11049CD37

What you can answer from here — as of July 09, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Lilotomab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In